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We present the case of an 18.5-year-old boy with hemophilia A and FVIII inhibitor detected at the age of 8 months. No persistent 
inhibitor eradication was achieved, despite three attempts of immune tolerance induction (ITI) with temporary inhibitor resolution and 
subsequent administration of 11 doses of rituximab. In spite of hemostatic treatment, rehabilitation, and radiosynovectomy, the patient 
suffered from recurrent bleeding episodes into almost all major joints, which resulted in the development of progressive hemophilic 
arthropathy. Currently, due to high frequency of bleeding episodes, the patient is being treated prophylactically and receives prophylaxis 
with activated prothrombin complex concentrate (aPCC).
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Introduction
Hemophilia A is an inherited bleeding diathesis resulting from decreased 
FVIII plasma activity, predisposing to an increased frequency of 
spontaneous bleeding episodes, mainly into joints and muscles. 
Hemophilia A patients receive intravenous concentrates of deficient 
clotting factor in order to treat bleeding episodes and prevent their 
reoccurrence. However, this management is associated with potentially 
negative immunological reaction to therapeutic FVIII due to possible 
development of anti-FVIII neutralizing antibodies (i.e., inhibitor). 
The abovementioned problem is observed mainly in patients with 
severe hemophilia A with an inhibitor prevalence of 10%–33% [1, 2]. 
A common therapy used in inhibitor eradication is immune tolerance 
induction (ITI) [3, 4].
Case report
Difficulties associated with the abovementioned treatment are 
illustrated in the presented case of hemophilia A patient who developed 
FVIII inhibitor. The patient was born in May 1998 (gravida 1, normal 
para 1). He was first hospitalized at the age of 8 months due to bleeding 
into the buttock. The family history of bleeding diathesis was negative. 
In a laboratory assessment of the patient’s coagulation system, APTT 
was indeterminable and subsequent evaluation of FVIII levels revealed 
very low values (<1% of active factor) of this clotting factor. Therefore, 
the patient was diagnosed with severe hemophilia A. Further tests 
revealed mutation of FVIII in the form of intron 22 inversion.
From his first bleeding episode, the patient received on-demand FVIII 
concentrate in a dose of 30 U/kg of body weight (BW).
All preventive vaccinations were administered subcutaneously in 
association with the prophylactic use of FVIII concentrate. From the 
beginning of the treatment, inhibitor titer evaluation was performed 
during every three to five courses of FVIII concentrate therapy. At 
the age of 16 months, after 36 courses of FVIII concentrate, lack of 
hemostatic effect after FVIII treatment was stated. At that time, the 
FVIII inhibitor level was 6.5 BU/ml and was increasing progressively. 
Next, the patient was implanted with a central venous catheter (Port-a-
Cath) in order to initiate ITI and attempt to eradicate inhibitor (inhibitor 
titer was 17 BU/ml at the time). As part of the ITI regimen, the patient 
received FVIII concentrate daily in a dose of 200 U/kg BW for 10 months 
(from September 1999 until July 2000). Unfortunately, an increase 
of inhibitor titer to 28 BU/ml was observed. Due to lack of factor VIII 
supplies and lack of response to FVIII replacement therapy, the dose 
was modified to 150 IU/kg BW three times per week. Regrettably, the 
abovementioned regimen was also ineffective and did not result in 
inhibitor eradication. Thus, in December 2000, after 15 months of use, 
we decided to withdraw this therapy. However, the patient’s situation 
was poor as he suffered from frequent hemarthroses and progressive 
arthropathy, which caused a significant decrease in his quality of life 
(QoL). Therefore, we made an attempt to use prophylactic treatment 
with activated prothrombin complex concentrate (aPCC). The boy who 
was almost 3 years old received aPCC in a dose of 80 U/kg BW 3 times 
per week. This therapy was conducted from March 2001 to February 
2002, when further treatment was withdrawn due to its ineffectiveness.
Owing to previous therapeutic failures, we decided to use on-demand 
sequential treatment with two bypassing agents only, recombinant 
activated factor VII (rFVIIa) and aPCC, instead of the previous regimen 
consisting of one bypassing agent administered during bleeding 
episodes.
Unfortunately, the abovementioned regimen was also ineffective. 
In February 2005, after 6 years of hemophilia A treatment, when the 
patient was 7 years old, we decided to try another prophylactic regimen 
consisting of rFVIIa, however, this time, in trial conditions. rFVIIa was 
used in a dose of 90 mg/kg BW for 3 months, up to May 2005. This 
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regimen resulted in a decrease in hemarthroses, yet it did not prevent 
their occurrence. At that time, inhibitor titer decreased to 1.5 BU/ml. 
For us, this small therapeutic success was an incentive for a second 
ITI regimen initiation. In May 2005, the second ITI regimen with FVIII 
concentrate (43 U/kg BW daily) was administered. After 14 months 
of therapy, we achieved decrease in inhibitor titer to 0.87 BU/ml. 
This was accompanied by a reduction in the frequency of bleeds. 
Unfortunately, after initial success, the inhibitor titer started to rise 
in the following month, reaching a level of 10 BU/ml. After the failure 
of the 2-year regimen, further ITI with FVIII was discontinued. In the 
period from June 2007 to September 2009, the patient received on-
demand bypass agents (i.e., rFVIIa and aPCC).
During this period, despite the patient’s participation in an additional 
original program of rehabilitation exercises for degenerative lesions, 
the frequency of bleeding episodes did not decrease. Arthropathy 
occurred in the right elbow joint (Pettersson score: 5 points, Colorado 
score: 7 points), left elbow joint (Pettersson score: 4 points, Colorado 
score: 6 points), left knee joint (Pettersson score: 4 points, Colorado 
score: 6 points), right knee joint (Pettersson score: 4 points, Colorado 
score: 6 points), right elbow joint (Pettersson score: 5 points, 
Colorado score: 7 points) and left elbow joint (Pettersson score: 4 
points, Colorado score: 6 points), left knee joints (Pettersson score: 
4 points, Colorado score: 6 points) and right knee joints (Pettersson 
score: 4 points, Colorado score: 6 points). In 2007, an Yttrium-90 
(90Y) synovectomy of both elbow joints was performed, leading 
to temporary reduction in bleeding episodes. At the beginning 
of September 2009, owing to inhibitor titer reduction <1 BU/ml, 
we decided to undertake a third attempt at ITI therapy, aiming to 
eradicate the inhibitor. This time, FVIII concentrate was given twice a 
day in a dose of 100 U/kg BW. The 2-month regimen resulted in an 
inhibitor titer negativization (<0.4 BU/ml). This therapeutic success 
resulted in a significant improvement of the patient’s QoL, enabling 
implementation of effective rehabilitation of the locomotor system. 
Unfortunately, after a subsequent year of follow-up treatment, we 
observed an increase in inhibitor titer >21 BU/ml.
Due to the ineffectiveness of previous therapeutic measures, after 
obtaining the approval of the Bioethics Committee of the Medical 
University of Warsaw and the patient’s parental consent, we decided 
to eradicate treatment-resistant inhibitor using rituximab 375 mg/m2, 
a widely advertised therapy at the time. The first dose of the new 
regimen was given in October 2010, and three subsequent doses 
were administered in 7-day intervals. Initial results were promising. 
After a fifth dose of rituximab, inhibitor titer reduction to <0.4 BU/
ml was obtained. Therefore, subsequent doses were given only 
on demand (i.e., only in the case of an inhibitor titer increase). The 
regimen was used for 3 years until May 2012. In total, the patient 
received 11 doses of rituximab. Unfortunately, the initial positive 
outcome of rituximab therapy was not persistent. In October 2013, 
after 3 years of treatment, an abrupt inhibitor titer increase of 
>18 BU/ml was observed. Therefore, no 12th dose of rituximab was 
given (Fig. 1). This was also the reason for ITI regimen discontinuation.
At that time, the patient was suffering from frequent hemarthroses, 
again mainly into knee and elbow joints. Radiosynovectomy of these 
joints was performed in order to stop the bleeding and resulted in 
a minimal reduction of the frequency of bleeding episodes with 
improvement of the patient’s QoL. Recurrent hemarthroses and 
inhibitor reoccurrence due to ineffectiveness of previous treatment, 
including rituximab, created a real problem concerning adjustment of 
further therapy of this 16-year-old patient. In April 2014, we decided 
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Fig. 1. Correlation between inhibitor level and subsequent doses of rituximab
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in order to reduce bleeding frequency. However, every attempt to 
decrease aPCC administration frequency, only by 1 day per week, 
resulted in joint bleeding. Thence, a daily aPCC regimen was 
maintained. In 2014, due to recurrent bleeding episodes, a right knee 
joint radiosynovectomy together with prophylactic use of rFVIIa was 
performed. Next, treatment with aPCC was continued. Currently, the 
patient aged 18.5 years is capable of walking unassisted through 
the city and attends school regularly. He also continues daily 
rehabilitation of the locomotor system. In physical examination, the 
only abnormalities were arthropathies of elbow and knee joints. 
During the last assessment (December 2017), FVIII inhibitor titer 
was 20 BU/ml. A daily aPCC regimen from August 2014 to November 
2017 resulted in no episodes of joint bleeding. Thus, we decided to 
reduce the number of aPCC treatment days by one per week. If in 
three subsequent months of therapy no episode of joint bleeding 
occurs, we plan to reduce frequency of treatment by another day.
Discussion
The therapy of patients with hemophilia A is based on replacement 
of deficient clotting factor factor, in order to prevent or stop an 
active bleeding episode. In most cases, this approach is effective. 
However, it may be associated with the risk of anti-FVIII antibody 
(the so-called inhibitor) development. Depending on the inhibitor 
level, this may limit the effectiveness of deficient coagulation factor 
concentrate administration [5, 6]. From the patients’ point of view, this 
is very dramatic as the use of deficient factor concentrate is actually 
the only method of effective hemophilia treatment. For patients with 
FVIII inhibitor, one solution is the use of bypassing agents, like aPCC 
and rFVIIa. Patients receive one to three doses of rFVIIa in two-hour 
intervals; rFVIIa is given between aPCC doses that are administered 
every 12 hours. Significantly better results were obtained, compared 
to the use of one bypassing agent [6]. Therefore, in patients with 
hemophilia and FVIII inhibitors, the main therapeutic aim is to 
develop the most effective method of inhibitor eradication. In the light 
of current knowledge, the most powerful method is immune tolerance 
induction (ITI), although its effectiveness in hemophilia patients is 
approximately 80%. The case of an 18.5-year-old male patient with 
hemophilia A diagnosed at the age of 8 months presented here is a 
clear example of ITI ineffectiveness. According to available data, it is 
believed that ITI effectiveness is indicated by the speed of inhibitor titer 
reduction to <0.4 BU/ml, normal FVIII recovery, and normal half-life 
time. Our research shows that we can distinguish effective, partially 
effective, or ineffective ITI [6]. With regard to the ineffectiveness 
of previous treatment of hemophilia A patients with inhibitors, 
increasing literature data suggest the use of anti-CD20 antibodies 
(i.e., rituximab at a dose of 375 mg/m2). Rituximab is a mouse-human 
chimeric monoclonal antibody manufactured with the use of genetic 
engineering methods. It is a glycosylated immunoglobulin containing 
constant human IgG1 regions and variable mouse regions composed 
of light and heavy chains.
Rituximab is manufactured in the culture of mammalian cell 
suspension (Chinese hamster ovary cells) and purified with the use 
of selective ion-exchange chromatography and specific methods 
of viral pathogens’ inactivation and removal. Except for its use in 
oncology and rheumatology, there are also reports on its efficacy 
in hematological conditions, including hemophilia with treatment-
resistant inhibitor [4]. Therefore, the abovementioned drug was given 
to our patients, yet the initial results of treatment were only temporary. 
In the presented case with high inhibitor titer and joint bleeding 
episodes, we also used another treatment option, i.e., prophylaxis 
with bypassing agents. It is believed that prophylactic use of aPCC 
can be recommended to patients with persisting inhibitor and 
recurrent joint bleeding episodes, when previous ITI was ineffective. 
This is also the case of patients not fulfilling criteria of ITI use and not 
giving their consent to this type of treatment.
Prophylactic use of aPCC reduces the number of bleeding episodes 
and may increase the effectiveness of ITI [7].
Above we have summarized all the data that can be found in literature 
to date. However, the question of clinical practice remains. The case 
we describe here indicates that despite the use of different available 
methods and initial successes, inhibitor eradication is not persistent. 
Moreover, because of the patient’s young age and the consequences 
of recurrent joint bleeding episodes, this case is very dramatic.
Regrettably, recurrent joint bleeding episodes were the biggest 
problem. Perhaps, our decision on radiosynovectomy at the age of 
9, when joint lesions are already significant (5 points on Pettersson 
scale), was made too late. Possibly, introduction of early, long-term 
prophylaxis with bypassing agents would be more effective.
A new therapeutic option for all hemophilia A with inhibitor is the use 
of Fc fusion technology (rFVIIIFc) to prolong circulation in the body. 
Recombinant factor VIII Fc fusion protein demonstrated rapid time to 
tolerization in high-risk first-time ITI patients [8].
Treatment of these disorders has focused on replacement of the missing 
coagulation factor to prevent or treat bleeding. New technologies 
and insights into hemostasis have driven the development of many 
promising new therapies for hemophilia and von Willebrand disease. 
Emerging bypass agents including zymogen-like factor IXa and Xa 
molecules are in development, and a bispecific antibody, emicizumab, 
demonstrated efficacy in phase 3 trial in people with hemophilia A and 
inhibitors. Tissue factor pathway inhibitor, the protein C/S system, and 
antithrombin are targets of novel compounds in development to alter 
the hemostatic balance, and new approaches using modified factor 
VIII molecules are being tested for prevention and eradication of 
inhibitor antibodies in hemophilia A [9, 10].
Results of the emicizumab test based on HAVEN 1–4 test are very 
promising [11, 12, 13]. HAVEN 2 was a nonrandomized, open-label 
trial of three dosing regimens (1.5 mg/kg BW administered weekly, 
3 mg/kg every 2 weeks, and 6 mg/kg every 4 weeks) given to 88 
children with hemophilia A complicated by inhibitor under the age 
of 12 years. These data have only been presented in an abstract 
form but demonstrated marked intraindividual reductions in treated 
bleeding events compared to their prior bypassing agent regimen. 
Young reported an overall 99% reduction in the annualized number 
of treated bleeding events compared to the prior bypassing agent 
regimen [14].
The benefits of emicizumab include bioavailability following 
subcutaneous administration, a long-acting effect allowing for reduced 
dosing frequency potentially as infrequent as once monthly, greater 
prophylactic efficacy, and benefits irrespective of the presence or 
absence of an inhibitor to FVIII. However, further investigations are 
needed.
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Today, we have a problem finding correct answers to all these 
questions. Furthermore, we do not know whether widespread 
prophylactic use of recombinant coagulation factor concentrates 
will impact properties of newly developed inhibitors and our ability 
to eradicate them. Therefore, the search for new methods and 
treatment options for hemophilia patients with inhibitor is crucial.
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